<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">KJIM</journal-id>
<journal-title-group>
<journal-title>The Korean Journal of Internal Medicine</journal-title></journal-title-group>
<issn pub-type="ppub">1226-3303</issn>
<issn pub-type="epub">2005-6648</issn>
<publisher>
<publisher-name>Korean Association of Internal Medicine</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3904/kjim.1998.13.2.77</article-id>
<article-id pub-id-type="publisher-id">kjim-13-2-77-1</article-id>
<article-categories>
<subj-group>
<subject>Original Article</subject></subj-group></article-categories>
<title-group>
<article-title>Cell Cycle Regulators during Human Atrial Development</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kim</surname><given-names>Won Ho</given-names></name>
<degrees>M.D.</degrees></contrib>
<contrib contrib-type="author">
<name><surname>Joo</surname><given-names>Chan Uhng</given-names></name>
<degrees>M.D.</degrees></contrib>
<contrib contrib-type="author">
<name><surname>Ku</surname><given-names>Ja Hong</given-names></name>
<degrees>M.D.</degrees></contrib>
<contrib contrib-type="author">
<name><surname>Ryu</surname><given-names>Chul Hee</given-names></name>
<degrees>M.D.</degrees><xref ref-type="aff" rid="af2-kjim-13-2-77-1"><sup>&#x0002A;</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>Koh</surname><given-names>Keum Nim</given-names></name>
<degrees>M.D.</degrees><xref ref-type="aff" rid="af3-kjim-13-2-77-1"><sup>&#x0002A;&#x0002A;</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>Koh</surname><given-names>Gou Young</given-names></name>
<degrees>M.D.</degrees><xref ref-type="aff" rid="af3-kjim-13-2-77-1"><sup>&#x0002A;&#x0002A;</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>Ko</surname><given-names>Jae Ki</given-names></name>
<degrees>M.D.</degrees><xref ref-type="corresp" rid="c1-kjim-13-2-77-1"/></contrib></contrib-group>
<aff id="af1-kjim-13-2-77-1">Institute of Cardiovascular Research, Chonbuk National University Medical School, Chonju, 560-180, Korea</aff>
<aff id="af2-kjim-13-2-77-1">
<label>&#x0002A;</label>Department of Obsterics and Gynecology, Chonbuk National University Medical School, Chonju, 560-180, Korea</aff>
<aff id="af3-kjim-13-2-77-1">
<label>&#x0002A;&#x0002A;</label>Cardiac Regeneration Group, Chonbuk National University Medical School, Chonju, 560-180, Korea</aff>
<author-notes>
<corresp id="c1-kjim-13-2-77-1">Address reprint requests to: Jae Ki Ko, M.D., Ph.D., Department of Internal Medicine and Institute of Cardiovascular Research Chonbuk National University School of Medicine San 2-20, Keum-Am-Dong Chonju, 560-180, Republic of Korea</corresp></author-notes>
<pub-date pub-type="ppub">
<month>7</month>
<year>1998</year></pub-date>
<volume>13</volume>
<issue>2</issue>
<fpage>77</fpage>
<lpage>82</lpage>
<permissions>
<copyright-statement>Copyright &#x000A9; 1998 The Korean Association of Internal Medicine</copyright-statement>
<copyright-year>1998</copyright-year>
<license>
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions>
<abstract>
<sec>
<title>Objectives</title>
<p>The molecular mechanisms that regulate cardiomyocyte cell cycle and terminal differentiation in humans remain largely unknown. To determine which cyclins, cyclin dependent kinases (CDKs) and cyclin kinase inhibitors (CKIs) are important for cardiomyocyte proliferation, we have examined protein levels of cyclins, CDKs and CKIs during normal atrial development in humans.</p></sec>
<sec>
<title>Methods</title>
<p>Atrial tissues were obtained in the fetus from inevitable abortion and in the adult during surgery, Cyclin and CDK proteins were determined by Western blot analysis, CDK activities were determined by phosphorylation amount using specific substrate.</p></sec>
<sec>
<title>Results</title>
<p>Most cyclins and CDKs were high during the fetal period and their levels decreased at different rates during the adult period. While the protein levels of cyclin D1, cyclin D3, CDK4, CDK6 and CDK2 were still detectable in adult atria, the protein levels of cyclin E, cyclin A, cyclin B, cdc2 and PCNA were not detectable. Interestingly, p27<sup>KIP 1</sup> protein increased markedly in the adult period, while p21<sup>C IP 1</sup> protein in atria was detectable only in the fetal period. While the activities of CDK6, CDK2 and cdc2 decreased markedly, the activity of CDK4 did not change from the fetal period to the adult period.</p></sec>
<sec>
<title>Conclusion</title>
<p>These findings indicate that marked reduction of protein levels and activities of cyclins and CDKs, and marked induction of p27<sup>KIP 1</sup> in atria, are associated with the withdrawal of cardiac cell cycle in adult humans.</p></sec></abstract>
<kwd-group>
<kwd>cyclin</kwd>
<kwd>CDK</kwd>
<kwd>CKI</kwd>
<kwd>atrium</kwd>
<kwd>cardiomyocytes</kwd>
<kwd>cell cycle</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>INTRODUCTION</title>
<p>Cardiomyocytes in the fetal development exhibit abundant proliferative capability, whereas cardiomyocytes in the adult mammals exhibit little, if any, capability to undergo cell division<sup><xref ref-type="bibr" rid="b1-kjim-13-2-77-1">1</xref>&#x02013;<xref ref-type="bibr" rid="b4-kjim-13-2-77-1">4</xref>)</sup>. Consequently, myocardial loss due to injury or disease during adulthood is irreversible, and the potential therapeutic value for myocardial regeneration is quite substantial. Knowledge of the mechanisms that control the cardiomyocyte cell cycle would allow us to design procedures to initiate repair or regeneration of the adult myocardium following injury. Unfortunately, we have yet to determine how the mammalian cardiomyocyte cell cycle is blocked after birth.</p>
<p>A number of cell-cycle regulated proteins have been identified and categorized as either cyclins, cyclin dependent kinases (CDKs) or cyclin dependent kinase inhibitors (CKIs)<sup><xref ref-type="bibr" rid="b5-kjim-13-2-77-1">5</xref>&#x02013;<xref ref-type="bibr" rid="b7-kjim-13-2-77-1">7</xref>)</sup>. The activity of CDKs control cell cycle progression, which activity is regulated positively and negatively by the association of CDKs with cyclins and CKIs, respectively<sup><xref ref-type="bibr" rid="b8-kjim-13-2-77-1">8</xref>, <xref ref-type="bibr" rid="b9-kjim-13-2-77-1">9</xref>)</sup>. Cyclins and CDKs are classified as G<sub>1</sub> (gap1), S (synthetic) or G<sub>2</sub> (gap2)/M (mitotic) phase proteins, depending on the role and protein abundance during the cell cycle<sup><xref ref-type="bibr" rid="b5-kjim-13-2-77-1">5</xref>&#x02013;<xref ref-type="bibr" rid="b7-kjim-13-2-77-1">7</xref>)</sup>. Presently, two families (INK and CIP/KIP) of CKIs exist, and include p15<sup>INK4B</sup>/p16<sup>INK4A</sup>/p18<sup>INK4C</sup>/p19<sup>INK4D</sup> and p21<sup>C IP 1</sup>/p27<sup>KIP 1</sup>/p57<sup>KIP2 <xref ref-type="bibr" rid="b10-kjim-13-2-77-1">10</xref>, <xref ref-type="bibr" rid="b11-kjim-13-2-77-1">11</xref>)</sup>. While the former family of CKIs bind to and inhibit only G<sub>1</sub> phase cyclin-CDK complexes, the latter family of CKIs bind to and inhibit G<sub>1</sub> and S phase cyclin-CDK complexes which leads to G<sub>1</sub>/G<sub>0</sub> cell cycle arrest<sup><xref ref-type="bibr" rid="b10-kjim-13-2-77-1">10</xref>, <xref ref-type="bibr" rid="b11-kjim-13-2-77-1">11</xref>)</sup>.</p>
<p>Recently, the importance of cell-cycle regulated proteins in cardiomyocytes has been recognized<sup><xref ref-type="bibr" rid="b12-kjim-13-2-77-1">12</xref>&#x02013;<xref ref-type="bibr" rid="b16-kjim-13-2-77-1">16</xref>)</sup>. Yoshizumi et al.<sup><xref ref-type="bibr" rid="b12-kjim-13-2-77-1">12</xref>)</sup> reported that the disappearance of cyclin A, which is involved in DNA synthesis, correlates with permanent withdrawal of cardiomyocytes from the cell cycle in human and rat hearts. We have reported the reduction of various cyclins and CDKs protein expressions with differential and dramatic decrease of CDK activities in cardiomyocytes during the neonatal period, and we have hypothesized that the functionally active cdc2 in neonatal cardiomyocytes is involved in binucleation formation<sup><xref ref-type="bibr" rid="b16-kjim-13-2-77-1">16</xref>)</sup>.</p>
<p>However, CDK activities and expression of CKIs in human hearts during development have not been examined. Therefore, we examined the expression and activities of cyclins, CDKs and CKIs in human atria during development in the human. We found that marked reduction of protein levels and activities of cyclins and CDKs, and marked induction of p27<sup>KIP 1</sup>, are associated with the withdrawal of cardiac cell cycle in adult humans.</p></sec>
<sec sec-type="materials|methods">
<title>MATERIALS AND METHODS</title>
<sec>
<title>Sampling</title>
<p>Since the sampling of fresh ventricular tissues is very difficult from adult humans, we have chosen the sampling of atrial tissue for this study. Atrial tissues of adult human were obtained from patients (48&#x02013;55 years old) with mitral valvular disease during open heart surgery. Atrial tissues of fetus were obtained from gestation week 12 and 25-old fetus whose mother underwent surgery due to threatened abortion or premature labor. All samplings were conducted in our hospital from July 1997 to November 1997. Informed consent was obtained from each patient. Atrial tissues were immediately frozen in liquid nitrogen and stored 70&#x000B0;C until assayed, while the remaining half of specimens were fixed in 10&#x00025; neutral formalin and routinely processed for pathologic study. Sprague-Dawley hosts and pregnant females were obtained from our breeding colony. Onset of pregnancy in female rats was determined by vaginal plug. Pregnant rats were killed at day 17 by decapitation and embryos were removed, decapitated and ventricles were harvested and stored in liquid nitrogen. Hearts were removed and ventricles were collected in the same manner from adult animals.</p></sec>
<sec>
<title>Western blot</title>
<p>Samples were homogenized in Nonidet P-40 buffer containing several protease inhibitors. Protein was quantitated, then separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) system and electrotransferred to nitrocellulose membranes<sup><xref ref-type="bibr" rid="b16-kjim-13-2-77-1">16</xref>)</sup>. The nitrocellulose membranes were blocked by incubation in blocking buffer, incubated with primary antibody, washed, incubated with horseradish peroxidase conjugated secondary antibody, and signals were visualized by the ECL detection method according to the manufacturer&#x02019;s protocol (Amersham Int. plc, Buckinghamshire, UK). Anti-cyclin D1 monoclonal antibody (72-13G), anti-cyclin D3 polyclonal antibody (C-16), anti-CDK4 polyclonal antibody (C22), anti-CDK2 polyclonal antibody (M2), anti-cdc2 polyclonal antibody (pSTAIRE), anti-PCNA monoclonal antibody (PC10), anti-p21<sup>C IP 1</sup> (C-19) and anti-p27<sup>KIP 1</sup> (N-20) were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Anti-cyclin A and anti-cyclin B monoclonal antibodies were generously provided by Dr. Michael Brandeis (ICRF Clare Hall Lab. Cell Cycle Control, UK).</p></sec>
<sec>
<title>Immunoprecipitation and assay of each CDK activity</title>
<p>To measure CDK4 or CDK2 activity, the method of Jahn et al.<sup><xref ref-type="bibr" rid="b17-kjim-13-2-77-1">17</xref>)</sup> was slightly modified<sup><xref ref-type="bibr" rid="b16-kjim-13-2-77-1">16</xref>)</sup>. Protein lysates (500 g) were diluted with 1 ml (final volume) of RIPA-buffer &#x0005B;1&#x00025; Triton X-100, 1&#x00025; sodium deoxycholate, 0.1&#x00025; sodium dodecyl sulfate (SDS), 0.15 M NaCl and 0.01 M Tris, pH 7.4&#x0005D; and precleaned with 50 <italic>&#x003BC;</italic>l of protein A-Sepharose CL-4B beads (0.15 g/ml, Pharmacia Biotech, Uppsala, Sweden) for 1 h at 4&#x000B0;C. The beads were then removed by centrifugation. Two g of CDK antibody was added to precleaned lysates in 1 ml of RIPA-buffer, and the mixture was gently rocked for 2 h at 4&#x000B0;C. Thirty <italic>&#x003BC;</italic>l of protein A-Sepharose CL-4B beads were added and the mixture was gently rocked for an additional 1 h at 4&#x000B0;C. Immunocomplexes were collected by centrifugation (3,000g, 3 min, 4&#x000B0;C) and washed three times with ice-cold RIPA-buffer. Half of the immunocomplex bound beads was eluted in sample buffer, separated by SDS-PAGE, and Western blot analysis was performed as described previously. Purified CDK kinase activity in immunoprecipitates was measured using a modification of the methods previously described<sup><xref ref-type="bibr" rid="b16-kjim-13-2-77-1">16</xref>)</sup>. Products of retinoblastoma protein (pRb, Santa Cruz) was used for determining the activities of CDK4 or CDK6 as the substrate. Histone H1 (Calbiochem, La Jolla, CA, USA) was used for determining the activities of CDK2 or cdc2 as the substrate. The remaining half of immunocomplexes bound beads was suspended in kinase buffer (10 mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 1 mM DTT, 50 mM HEPES-NaOH, pH 7.3) and washed twice in kinase buffer. Reactions were carried out in kinase buffer (final volume, 50 <italic>&#x003BC;</italic>l) with 0.1 <italic>&#x003BC;</italic>g of pRb or 2.5 <italic>&#x003BC;</italic>g of histone H1, 0.1 mM ATP and 5.0 <italic>&#x003BC;</italic>Ci &#x0005B;&#x003B3;-<sup>32</sup>P&#x0005D;ATP at 30&#x000B0;C for 20 minutes and stopped by adding 2&#x000D7; SDS sample buffer. The optimum incubation time was determined by measuring several time points of pRb or histone H1 phosphorylation (data not shown). Final reactants were separated using SDS-PAGE, fixed with 5 to 10 volumes of glacial acetic acid:methanol:water (10:20:70), dried and autoradiographed. Signals were quantified using densitometry.</p></sec></sec>
<sec sec-type="results">
<title>RESULTS</title>
<sec>
<title>Temporal changes of cyclin protein levels in human atria during the fetal and adult period (<xref ref-type="fig" rid="f1-kjim-13-2-77-1">Fig. 1</xref>)</title>
<p>Anti-cyclin D1 antibody recognized two cyclin D1 bands that indicated phosphorylation status. The two cyclin D1 bands were readily detectable at gestation 12 weeks (G12W) and gestation 25 weeks (G25W). As the phosphorylated active from cyclin D1 (upper band) disappeared, the dephosphorylated inactive from cyclin D1 (lower band) was detectable at the adult period. The cyclin D3 levels decreased gradually from the early fetal period to the adult period. Cyclin E, A and B levels were high at G12W, decreased gradually at G25W and were not detectable at the adult period.</p></sec>
<sec>
<title>Temporal changes of CDK protein levels in rat ventricles and human atria during the fetal and adult period (<xref ref-type="fig" rid="f2-kjim-13-2-77-1">Fig. 2</xref>)</title>
<p>The protein levels of CDKs and PCNA were high at the fetal period and their levels decreased markedly at the adult period in the rat. The CDK4 and CDK6 levels were high at G12W in human atria, and those did not change during the fetal period. Interestingly, while CDK4 levels did not change, CDK6 levels decreased from the fetal period to the adult period. CDK2, cdc2 and PCNA levels were high at G12W, decreased gradually at G25W and decreased markedly at the adult period.</p></sec>
<sec>
<title>Changes of CDK activities in human atria during fetal and adult period (<xref ref-type="fig" rid="f3-kjim-13-2-77-1">Fig. 3</xref>)</title>
<p>The specific antibodies for CDKs that were used for Western blot analysis were used to purify and measure the functional activities of CDKs. Each antibody bound its respective protein in atrial lysates, and these immune complexes were immunoprecipitated as confirmed by Western blotting (data not shown). While CDK4 activity did not change from the fetal period to the adult period, activities of CDK6, CDK2 and cdc2 decreased markedly. The ratio (adult period to fetal period) of each CDK activity was 0.89 0.11 (CDK4, n&#x0003D;3, not significant), 0.12 0.02(CDK6, n&#x0003D;3, p&lt;0.05), 0.18 0.04 (CDK2, n&#x0003D;3, p&lt;0.05, CDK2) and 0.09 0.02 (cdc2, n&#x0003D;3, p&lt;0.05)</p></sec>
<sec>
<title>Temporal changes of p21<sup>C IP 1</sup> and p27<sup>KIP 1</sup> protein levels in human atria during fetal and adult period (<xref ref-type="fig" rid="f2-kjim-13-2-77-1">Fig. 2</xref>)</title>
<p>The protein levels of p21<sup>C IP 1</sup> and p27<sup>KIP 1</sup> were readily detectable in atria during the fetal period. Interestingly, while p21<sup>C IP 1</sup> in atria was not detectable at the adult period, the protein levels of p27<sup>KIP 1</sup> increased (5.6&#x000B1;1.2 fold, n&#x0003D;3, p,0.05) significantly in the adult period.</p></sec></sec>
<sec sec-type="discussion">
<title>DISCUSSION</title>
<p>The present study is designed to determine the changes of cyclins, CDKs and CKI proteins in human atria during the fetal and adult periods. These findings indicated that the protein levels of most cyclins and CDKs were high in atria during the fetal period, then they decreased at different rates. While the activities of CDK6, CDK2 and cdc2 decreased markedly, the activity of CDK4 was not changed. While p21<sup>C IP 1</sup> protein in atria was detectable only in the fetal period, p27<sup>KIP 1</sup> protein increased markedly in the adult period. In this study, cardiomyocytes may have contributed greatly to the levels of cyclin, CDK and CKIs from whole atria, though contribution of non-myocytes could not be ruled out. These findings indicate that reduction of cyclin and CDK levels, and induction of p27<sup>KIP 1</sup> level, are associated with the withdrawal of atrial cell cycle and block the ability of adult cardiomyocytes to re-enter the cell cycle after injury.</p>
<p>The mammalian cell cycle consists of G<sub>1</sub>, S, G<sub>2</sub>, and M phases. D-type cyclins are synthesized in early G1 phase, and they bind to and activate CDK4 as cells leave the quiescent phase<sup><xref ref-type="bibr" rid="b5-kjim-13-2-77-1">5</xref>&#x02013;<xref ref-type="bibr" rid="b7-kjim-13-2-77-1">7</xref>)</sup>. The cyclin D/cyclin D complex phosphorylates retinoblastoma protein (Rb) in the late G1 phase of cell cycle, canceling Rbs growth-suppressive function and, thereby, facilitating S-phase entry. DNA synthesis occurs in the S phase of cell cycle with activation of cyclin E, A<sup><xref ref-type="bibr" rid="b8-kjim-13-2-77-1">8</xref>, <xref ref-type="bibr" rid="b9-kjim-13-2-77-1">9</xref>)</sup>. Binding of cyclin A or E is necessary for activation CDK2. Cyclin B binds to cyclin B and controls entry into mitosis<sup><xref ref-type="bibr" rid="b8-kjim-13-2-77-1">8</xref>, <xref ref-type="bibr" rid="b9-kjim-13-2-77-1">9</xref>)</sup>. Thus, the previous<sup><xref ref-type="bibr" rid="b16-kjim-13-2-77-1">16</xref>)</sup> and the present studies indicate that cyclins and CDKs are actively involved in cell cycle progression of cardiomyocytes during the fetal period. There is a rapid transition from G<sub>1</sub>/M phase of cell cycle to G<sub>0</sub>/G<sub>1</sub> phase of cell cycle in cardiomyocytes during the late gestational and early neonatal periods in experimental animals<sup><xref ref-type="bibr" rid="b18-kjim-13-2-77-1">18</xref>, <xref ref-type="bibr" rid="b19-kjim-13-2-77-1">19</xref>)</sup>.</p>
<p>Yoshizumi <italic>el al.</italic>,<sup><xref ref-type="bibr" rid="b12-kjim-13-2-77-1">12</xref>)</sup> and our previous data<sup><xref ref-type="bibr" rid="b16-kjim-13-2-77-1">16</xref>)</sup>, suggested that disappearance of cyclin A was correlated with withdrawal of cardiomyocytes from the cell cycle in human and rat hearts. In addition, the present data indicate that disappearance of cyclin E or B also may be a candidate cyclin for withdrawal of cardiomyocytes from the cell cycle in human atrium. D-type cyclins are synthesized as long as growth factor stimulation is persistent<sup><xref ref-type="bibr" rid="b5-kjim-13-2-77-1">5</xref>&#x02013;<xref ref-type="bibr" rid="b7-kjim-13-2-77-1">7</xref>)</sup>. However, they are rapidly degraded when growth factors or mitogens are withdrawn, regardless of the position of the cell in the cell cycle. Growth factors act on adult hearts in an autocrine or paracrine manner<sup><xref ref-type="bibr" rid="b20-kjim-13-2-77-1">20</xref>&#x02013;<xref ref-type="bibr" rid="b22-kjim-13-2-77-1">22</xref>)</sup> and may induce relatively constant D-type cyclins. In this study, adult atria expressed cyclin D1 and D3 proteins. A similar pattern was also observed in rat hearts during development<sup><xref ref-type="bibr" rid="b16-kjim-13-2-77-1">16</xref>)</sup>.</p>
<p>In order to function in the cell cycle, each cyclin must bind to a specific CDK<sup><xref ref-type="bibr" rid="b8-kjim-13-2-77-1">8</xref>, <xref ref-type="bibr" rid="b9-kjim-13-2-77-1">9</xref>)</sup>. Most CDK protein levels and activities were high in atria during the fetal period and those were very low or undetectable levels during the adult periods. Hence, most CDKs could influence the cardiomyocyte cell cycle. PCNA, a DNA polymerase-associated protein, was used as a marker for cell proliferation<sup><xref ref-type="bibr" rid="b23-kjim-13-2-77-1">23</xref>)</sup>. The temporal pattern of PCNA during cardiac development was similar to the pattern of CDKs and was consistent with another report<sup><xref ref-type="bibr" rid="b24-kjim-13-2-77-1">24</xref>)</sup>. However, no significant changes occurred in levels and activities in CDK4 during development in human atrium. It is not clear why there is a species difference between rats and humans<sup><xref ref-type="bibr" rid="b16-kjim-13-2-77-1">16</xref>)</sup>.</p>
<p>The present data indicate that the protein levels of p27<sup>KIP 1</sup> increased significantly in the adult atria. The actual nuclear amount of p27<sup>KIP 1</sup> in cardiomyocytes may be increased more if we account the decreased ratio of nuclear/cytoplasmic volume between the fetal and adult period<sup><xref ref-type="bibr" rid="b25-kjim-13-2-77-1">25</xref>&#x02013;<xref ref-type="bibr" rid="b27-kjim-13-2-77-1">27</xref>)</sup>. Because the amount of p27<sup>KIP 1</sup> protein paralleled temporally the inhibition of CDK activity in all instances investigated, the protein abundance is likely the primary mode of p27<sup>KIP 1</sup> action<sup><xref ref-type="bibr" rid="b8-kjim-13-2-77-1">8</xref>, <xref ref-type="bibr" rid="b9-kjim-13-2-77-1">9</xref>)</sup>. Therefore, these present data suggest that the high levels of p27<sup>KIP 1</sup> protein in atria at the adult period may be a principal inhibitor for cardiomyocyte cell cycle progression after injury. The transgenic animal model, with its selective gene disruption, provides an invaluable tool for understanding the <italic>in-vivo</italic> function of a selected gene. While all organs have detectable amounts of p27<sup>KIP 1</sup>, it is most abundant in the thymus and spleen in mice<sup><xref ref-type="bibr" rid="b28-kjim-13-2-77-1">28</xref>&#x02013;<xref ref-type="bibr" rid="b30-kjim-13-2-77-1">30</xref>)</sup> and rats &#x0005B;our laboratory unpublished observation&#x0005D;. Hearts have approximately 20&#x02013;25&#x00025; of p27<sup>KIP 1</sup> protein compared to the spleen in rats &#x0005B;our laboratory unpublished observation&#x0005D;. Transgenic mice lacking p27<sup>KIP 1</sup> have grossly normal development but display several phenotypes linked to increased cell proliferation<sup><xref ref-type="bibr" rid="b28-kjim-13-2-77-1">28</xref>&#x02013;<xref ref-type="bibr" rid="b30-kjim-13-2-77-1">30</xref>)</sup> such as increased body size and multiple organ hyperplasia. A positive correlation between the expression amount of p27<sup>KIP 1</sup> protein in an organ and the increase in weight of the organ following p27<sup>KIP 1</sup> gene disruption was observed. Thus, while there is a 1.8-fold increase of weight in spleen and thymus, 1.2&#x02013;1.3-fold increase of weight in brain and heart were observed in the p27<sup>KIP 1</sup>-lacking mice<sup><xref ref-type="bibr" rid="b29-kjim-13-2-77-1">29</xref>)</sup>. The increased organ weights result from more increased cell cycle. These results from mice lacking p27<sup>KIP 1</sup> strongly support our data that mainly p27<sup>KIP 1</sup> limits cell proliferation by inhibiting G<sub>1</sub> and S phase cyclin-CDK complexes in cardiomyocytes during development and after injury.</p></sec>
<sec sec-type="conclusions">
<title>SUMMARY</title>
<p>We have shown that cyclins, CDKs and the CIP/KIP family of CKIs are highly detectable in human atriums during the fetal period and that, differential change occurred at the adult period. Marked reduction of protein levels and activities of cyclins and CDKs are responsible for withdrawal of atrial cardiomyocytes from the cell cycle. Notably, marked induction of p27<sup>KIP 1</sup> in adult atrium may be an important inhibitor for blocking the ability of adult cardiomyocytes to re-enter the cell cycle after injury.</p></sec></body>
<back>
<ack>
<p>This work was supported by research funds of Chonbuk National University (1996&#x02013;1997) and KSTEPI (1997&#x02013;1998).</p></ack>
<ref-list>
<title>REFERENCES</title>
<ref id="b1-kjim-13-2-77-1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>RO</given-names></name><name><surname>Baserga</surname><given-names>R</given-names></name></person-group><article-title>Nucleic acid and protein synthesis in cardiac muscle of growing and adult mice</article-title><source>Exp Cell Res</source><year>1965</year><volume>40</volume><fpage>340</fpage><lpage>352</lpage></mixed-citation></ref>
<ref id="b2-kjim-13-2-77-1"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rumyantsev</surname><given-names>PP</given-names></name></person-group><article-title>Interrelationship of the prolifeartion and differentiation processes during cardiac myogenesis and regeneration</article-title><source>Int Rev Cytol</source><year>1977</year><volume>51</volume><fpage>187</fpage><lpage>273</lpage></mixed-citation></ref>
<ref id="b3-kjim-13-2-77-1"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clubb</surname><given-names>FJ</given-names><suffix>Jr</suffix></name><name><surname>Bishop</surname><given-names>SP</given-names></name></person-group><article-title>Formation of binucleated myocardial cells in the neonatal rat</article-title><source>Lab Invest</source><year>1984</year><volume>50</volume><fpage>571</fpage><lpage>577</lpage></mixed-citation></ref>
<ref id="b4-kjim-13-2-77-1"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claycomb</surname><given-names>WC</given-names></name></person-group><article-title>Control of cardiac muscle division</article-title><source>Trend Cardiovas</source><year>1992</year><volume>2</volume><fpage>231</fpage><lpage>236</lpage></mixed-citation></ref>
<ref id="b5-kjim-13-2-77-1"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>T</given-names></name><name><surname>Pines</surname><given-names>J</given-names></name></person-group><article-title>Cyclins and cancer</article-title><source>Cell</source><year>1991</year><volume>66</volume><fpage>1071</fpage><lpage>1074</lpage></mixed-citation></ref>
<ref id="b6-kjim-13-2-77-1"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>T</given-names></name><name><surname>Pines</surname><given-names>J</given-names></name></person-group><article-title>Cyclins and cancer II: cyclin D and CDK inhibitors come to age</article-title><source>Cell</source><year>1994</year><volume>79</volume><fpage>573</fpage><lpage>582</lpage></mixed-citation></ref>
<ref id="b7-kjim-13-2-77-1"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><article-title>G1 phase progression: cycling on cue</article-title><source>Cell</source><year>1994</year><volume>79</volume><fpage>551</fpage><lpage>555</lpage></mixed-citation></ref>
<ref id="b8-kjim-13-2-77-1"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>DO</given-names></name></person-group><article-title>Priciples of CDK regulation</article-title><source>Nature</source><year>1995</year><volume>374</volume><fpage>131</fpage><lpage>134</lpage></mixed-citation></ref>
<ref id="b9-kjim-13-2-77-1"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lees</surname><given-names>E</given-names></name></person-group><article-title>Cyclin dependent kinase regulation</article-title><source>Curr Opi Cell Biol</source><year>1995</year><volume>7</volume><fpage>773</fpage><lpage>780</lpage></mixed-citation></ref>
<ref id="b10-kjim-13-2-77-1"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>JW</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name></person-group><article-title>CDK inhibitors in development and cancer</article-title><source>Curr Opin Genet Dev</source><year>1996</year><volume>6</volume><fpage>56</fpage><lpage>64</lpage></mixed-citation></ref>
<ref id="b11-kjim-13-2-77-1"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><article-title>Cancer cell cycles</article-title><source>Science</source><year>1996</year><volume>274</volume><fpage>1672</fpage><lpage>1677</lpage></mixed-citation></ref>
<ref id="b12-kjim-13-2-77-1"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshizumi</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name><name><surname>Hsieh</surname><given-names>CM</given-names></name><name><surname>Tsai</surname><given-names>JC</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Perrella</surname><given-names>MA</given-names></name><name><surname>Patterson</surname><given-names>C</given-names></name><name><surname>Endege</surname><given-names>WO</given-names></name><name><surname>Schlegel</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>ME</given-names></name></person-group><article-title>Disappearance of cyclin A correlates with permanent withdrawal of cardiomyocytes from the cell cycle in human and rat hearts</article-title><source>J Clin invest</source><year>1995</year><volume>95</volume><fpage>2275</fpage><lpage>2280</lpage></mixed-citation></ref>
<ref id="b13-kjim-13-2-77-1"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGill</surname><given-names>CJ</given-names></name><name><surname>Brooks</surname><given-names>G</given-names></name></person-group><article-title>Cell cycle control mechanisms and their role in cardiac growth</article-title><source>Cardiovas Res</source><year>1995</year><volume>30</volume><fpage>557</fpage><lpage>569</lpage></mixed-citation></ref>
<ref id="b14-kjim-13-2-77-1"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Chae</surname><given-names>SW</given-names></name><name><surname>Koh</surname><given-names>KM</given-names></name><name><surname>Koh</surname><given-names>GY</given-names></name></person-group><article-title>Cyclins and cyclin dependent kinases during cardiac development</article-title><source>Mol Cells</source><year>1997</year><volume>7</volume><fpage>360</fpage><lpage>366</lpage></mixed-citation></ref>
<ref id="b15-kjim-13-2-77-1"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadoshima</surname><given-names>J</given-names></name><name><surname>Aoki</surname><given-names>H</given-names></name><name><surname>Izumo</surname><given-names>S</given-names></name></person-group><article-title>Angiotensin II and serum differentially regulate expression of cyclins, activity of cyclin-dependent kinases and phosphorylation of pRb in neonatal cardiomyocytes</article-title><source>Circ Res</source><year>1997</year><volume>80</volume><fpage>228</fpage><lpage>241</lpage></mixed-citation></ref>
<ref id="b16-kjim-13-2-77-1"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>MJ</given-names></name><name><surname>Koh</surname><given-names>GY</given-names></name></person-group><article-title>Differential and dramatic changes of cyclin dependent kinase activities in cardiomyocytes during the neonatal period</article-title><source>J Mol Cell Cardiol</source><year>1997</year><volume>29</volume><fpage>1767</fpage><lpage>1777</lpage></mixed-citation></ref>
<ref id="b17-kjim-13-2-77-1"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jahn</surname><given-names>L</given-names></name><name><surname>Sadishima</surname><given-names>J</given-names></name><name><surname>Izumo</surname><given-names>S</given-names></name></person-group><article-title>Cyclins and cyclin-dependent kinases are differentially regulated during terminal differentiation of C2C12 muscle cells</article-title><source>Exp Cell Res</source><year>1994</year><volume>212</volume><fpage>297</fpage><lpage>307</lpage></mixed-citation></ref>
<ref id="b18-kjim-13-2-77-1"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erokhina</surname><given-names>IL</given-names></name><name><surname>Rumyantsev</surname><given-names>PP</given-names></name></person-group><article-title>Proliferation and biosynthetic activities of myocytes from the conductive system and working myocardium of the developing mouse heart. Light microscopic autoradiographic study</article-title><source>Acta Histochem</source><year>1988</year><volume>84</volume><fpage>51</fpage><lpage>66</lpage></mixed-citation></ref>
<ref id="b19-kjim-13-2-77-1"><label>19.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rumyantsev</surname><given-names>PP</given-names></name></person-group><source>Growth and Hyperplasia of Cardiac Muscle Cells</source><fpage>70</fpage><lpage>199</lpage><publisher-name>Harwood Academic Publisher</publisher-name><year>1991</year></mixed-citation></ref>
<ref id="b20-kjim-13-2-77-1"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casscells</surname><given-names>W</given-names></name><name><surname>Bazoberry</surname><given-names>F</given-names></name><name><surname>Speir</surname><given-names>E</given-names></name><name><surname>Thompson</surname><given-names>N</given-names></name><name><surname>Flanders</surname><given-names>K</given-names></name><name><surname>Kondaiah</surname><given-names>P</given-names></name><name><surname>Ferrans</surname><given-names>VJ</given-names></name><name><surname>Epstein</surname><given-names>SE</given-names></name><name><surname>Sporn</surname><given-names>M</given-names></name></person-group><article-title>Transforming growth factor-&#x003B2; in normal heart and myocardiac infarction</article-title><source>Ann NY Acad Sci</source><year>1991</year><volume>593</volume><fpage>148</fpage><lpage>161</lpage></mixed-citation></ref>
<ref id="b21-kjim-13-2-77-1"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelmann</surname><given-names>GL</given-names></name><name><surname>Boehm</surname><given-names>KD</given-names></name><name><surname>Haskell</surname><given-names>JF</given-names></name><name><surname>Khairallah</surname><given-names>PA</given-names></name><name><surname>Ilan</surname><given-names>J</given-names></name></person-group><article-title>Insulin-like growth factors and neonatal cardiomyocyte development: Ventricular gene expression and membrane receptor variation in normotensive and hypertensive rats</article-title><source>Mol Cell Endocrinol</source><year>1989</year><volume>63</volume><fpage>1</fpage><lpage>14</lpage></mixed-citation></ref>
<ref id="b22-kjim-13-2-77-1"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelmann</surname><given-names>GL</given-names></name><name><surname>Dionne</surname><given-names>CA</given-names></name><name><surname>Jaye</surname><given-names>MC</given-names></name></person-group><article-title>Acidic fibroblast growth factor and heart development</article-title><source>Circ Res</source><year>1993</year><volume>72</volume><fpage>7</fpage><lpage>19</lpage></mixed-citation></ref>
<ref id="b23-kjim-13-2-77-1"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marino</surname><given-names>TA</given-names></name><name><surname>Haldar</surname><given-names>S</given-names></name><name><surname>Williamson</surname><given-names>EC</given-names></name><name><surname>Beaverson</surname><given-names>K</given-names></name><name><surname>Walter</surname><given-names>RA</given-names></name><name><surname>Marino</surname><given-names>DR</given-names></name><name><surname>Beatty</surname><given-names>C</given-names></name><name><surname>Lipson</surname><given-names>K</given-names></name></person-group><article-title>Prolifearting cell nuclear antigen in developing and adult rat cardiac muscle cells</article-title><source>Circ Res</source><year>1991</year><volume>69</volume><fpage>1353</fpage><lpage>1360</lpage></mixed-citation></ref>
<ref id="b24-kjim-13-2-77-1"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bravo</surname><given-names>R</given-names></name><name><surname>Frank</surname><given-names>R</given-names></name><name><surname>Blundell</surname><given-names>PA</given-names></name><name><surname>MacDonald-Bravo</surname><given-names>H</given-names></name></person-group><article-title>Cyclin/PCNA is the auxiliary protein of DNA polymerase-</article-title><source>Nature</source><year>1987</year><volume>326</volume><fpage>515</fpage><lpage>517</lpage></mixed-citation></ref>
<ref id="b25-kjim-13-2-77-1"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anversa</surname><given-names>P</given-names></name><name><surname>Olivetti</surname><given-names>G</given-names></name><name><surname>Loud</surname><given-names>AV</given-names></name></person-group><article-title>Morphometric study of early postnatal development in the left and right ventricular myocardium of the rat. I. Hypertrophy hyperplasia, and binucleation of myocytes</article-title><source>Circ Res</source><year>1980</year><volume>46</volume><fpage>495</fpage><lpage>502</lpage></mixed-citation></ref>
<ref id="b26-kjim-13-2-77-1"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivetti</surname><given-names>G</given-names></name><name><surname>Anversa</surname><given-names>P</given-names></name><name><surname>Loud</surname><given-names>AV</given-names></name></person-group><article-title>Morphometric study of early postnatal development in the left and right ventricular myocardium of the rat</article-title><source>Circ Res</source><year>1980</year><volume>46</volume><fpage>503</fpage><lpage>512</lpage></mixed-citation></ref>
<ref id="b27-kjim-13-2-77-1"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Capasso</surname><given-names>JM</given-names></name><name><surname>Gerdes</surname><given-names>AM</given-names></name></person-group><article-title>Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development</article-title><source>J Mol Cell Cardiol</source><year>1996</year><volume>28</volume><fpage>1737</fpage><lpage>1746</lpage></mixed-citation></ref>
<ref id="b28-kjim-13-2-77-1"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Ishida</surname><given-names>N</given-names></name><name><surname>Shirane</surname><given-names>M</given-names></name><name><surname>Inomata</surname><given-names>A</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Shishido</surname><given-names>N</given-names></name><name><surname>Horii</surname><given-names>I</given-names></name><name><surname>Loh</surname><given-names>DY</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name></person-group><article-title>Mice lacking p27<sup>KIP 1</sup>display increased body size, multiple organ hyperplasia, retinal dysplasia and pituitary tumors</article-title><source>Cell</source><year>1996</year><volume>85</volume><fpage>707</fpage><lpage>720</lpage></mixed-citation></ref>
<ref id="b29-kjim-13-2-77-1"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiyokawa</surname><given-names>H</given-names></name><name><surname>Kineman</surname><given-names>RD</given-names></name><name><surname>Manova-Todorova</surname><given-names>KO</given-names></name><name><surname>Soares</surname><given-names>VC</given-names></name><name><surname>Hoffman</surname><given-names>ES</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>Khanam</surname><given-names>D</given-names></name><name><surname>Hayday</surname><given-names>AC</given-names></name><name><surname>Frohman</surname><given-names>LA</given-names></name><name><surname>Koff</surname><given-names>A</given-names></name></person-group><article-title>Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27<sup>KIP 1</sup></article-title><source>Cell</source><year>1996</year><volume>85</volume><fpage>721</fpage><lpage>732</lpage></mixed-citation></ref>
<ref id="b30-kjim-13-2-77-1"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fero</surname><given-names>ML</given-names></name><name><surname>Rivkin</surname><given-names>M</given-names></name><name><surname>Tasch</surname><given-names>M</given-names></name><name><surname>Porter</surname><given-names>P</given-names></name><name><surname>Carow</surname><given-names>CE</given-names></name><name><surname>Firpo</surname><given-names>E</given-names></name><name><surname>Polyak</surname><given-names>K</given-names></name><name><surname>Tsau</surname><given-names>LH</given-names></name><name><surname>Broudy</surname><given-names>V</given-names></name><name><surname>Perlmutter</surname><given-names>RM</given-names></name><name><surname>Kaushansky</surname><given-names>K</given-names></name><name><surname>Roberts</surname><given-names>JM</given-names></name></person-group><article-title>A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis and female sterility in p27<sup>KIP 1</sup>-deficient mice</article-title><source>Cell</source><year>1996</year><volume>85</volume><fpage>733</fpage><lpage>744</lpage></mixed-citation></ref></ref-list>
<sec sec-type="display-objects">
<title>Figures</title>
<fig id="f1-kjim-13-2-77-1" position="float">
<label>Fig. 1.</label>
<caption>
<p>Temporal changes of cyclin in atria during the fetal and adult periods. Parallel blots with total lysate protein (50 <italic>&#x003BC;</italic>g) of atria are from gestational week 12 (G12W) and 25 (G25W) of a 55 year-old (ADULT). The antibodies used for each blot were described in the MATERIALS AND METHODS section. Results were similar to three separate experiments.</p></caption>
<graphic xlink:href="kjim-13-2-77-1f1.tif"/></fig>
<fig id="f2-kjim-13-2-77-1" position="float">
<label>Fig. 2.</label>
<caption>
<p>Temporal changes of CDK protein levels in rat ventricles and human atria during the fetal and adult periods. Parallel blots with total lysate protein (50 <italic>&#x003BC;</italic>g) of ventricles are from gestational day 17 (FT) and 150 day old (AD) ventricles in the rat and atria are from fetal gestational week 12 (G12W) and 25 (G25W) of a 55 year-old (AD) human. The antibodies used for each blot were described in the MATERIALS AND METHODS section. Results were similar to three separate experiments.</p></caption>
<graphic xlink:href="kjim-13-2-77-1f2.tif"/></fig>
<fig id="f3-kjim-13-2-77-1" position="float">
<label>Fig. 3.</label>
<caption>
<p>Temporal changes of activities of CDKs in atria during the fetal and adult periods. Autoradiographic analyses were performed for activities of CDKs from immunoprecipitated complexes. pRb was used as substrate for CDK4 or CDK6 activities. Histone H1 was used as substrate for CDK2 and cdc2 activities. The detailed protocol is described in the MATERIALS AND METHODS section. The legends of ages are the same as shown in <xref ref-type="fig" rid="f1-kjim-13-2-77-1">Fig. 1</xref>. Results were similar to three separate experiments.</p></caption>
<graphic xlink:href="kjim-13-2-77-1f3.tif"/></fig>
<fig id="f4-kjim-13-2-77-1" position="float">
<label>Fig. 4.</label>
<caption>
<p>Temporal changes of p21<sup>C IP 1</sup> and p27<sup>KIP 1</sup> in atria during the fetal and adult periods. Parallel blots with total lysate protein (50 <italic>&#x003BC;</italic>g) of atria are from gestational week 12 (G12W) and 25 (G25W) of a 55 year-old (ADULT). The antibodies used for each blot were described in the MATERIALS AND METHODS section. Results were similar to three separate experiments.</p></caption>
<graphic xlink:href="kjim-13-2-77-1f4.tif"/></fig></sec></back></article>
